Search clinical trials for: GLP-1 agonist

Total 58151 results

University of Bath
Arla Foods

Completed

The Dose Response of Calcium Co-ingested With Protein on GLP-1 Concentrations (PROCAL)

GLP-1 Concentration

United Kingdom
Instituto Nacional de Ciencias Medicas y Nutricion...

Completed

Effects of Sucralose in Gut Intestinal Microbiota and Postprandial GLP-1

Gut Microbiota | GLP-1

Mexico
Adrian Vella

Completed

Dose-response Study of Exendin-9,39 on Glucose Metabolism

Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1

United States
Rigshospitalet, Denmark
Department of Cardiovascular and Renal Research, University of Southern Denmark

Completed

Acute Effects of GLP-1 on Renal Hemodynamics (GLP1RRBF)

The GLP-1-mediated Gut-kidney Axis

Denmark
Indonesia University
Dr Cipto Mangunkusumo General Hospital; SEAMEO Regional Centre for Food and...

Completed

The Comparison of PYY, Ghrelin, GLP1, Glucose Level, Level of Satiety, and Ad Libitum Intake in Obese and Non-Obese Patients After Breakfast With Balanced Macronutrient Composition

Obesity | Ghrelin | Appetite | Gut Hormones | PYY | VAS of Satiety | VAS of Hunger | GLP - 1

Indonesia
Third Military Medical University

Unknown

Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment (Par-4；GLP-1)

GLP-1；Metformin；Telomere-telomerase System；Par-4

China
Hvidovre University Hospital

Unknown

The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate (ALFA-1)

Type 1 Diabetes
University Hospital, Gentofte, Copenhagen
University of Copenhagen

Unknown

Atropin and Glucose Stimulated Insulinsecretion and the Cephalic Insulin Response

The Focus of This Study is to Evaluete the Significances of the Vagal Cholinerg Nervuos System for the Effect of GLP-1 by Using Atropin Administration.

Denmark
Medical University of South Carolina

Completed

Effects of GLP-1 Agonists on Gastric Volume

Diabetes | Glucagon-like Peptide 1 | GLP-1 | Gastric Content Aspiration

United States
Zealand Pharma
Profil Institut für Stoffwechselforschung GmbH

Recruiting

A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Safety and Tolerability

Germany
Ludwig-Maximilians - University of Munich
German Research Foundation; Merck Sharp & Dohme LLC

Completed

Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans

Hyperglycemia

Germany
Zealand Pharma

Completed

A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Healthy

Germany
Anders Fink-Jensen, MD, DMSci

Recruiting

Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

Schizophrenia | Type 2 Diabetes | Metabolic Disturbance | Clozapine | Olanzapine | GLP-1

Denmark
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (GETGOAL-S)

Diabetes Mellitus, Type 2

United States, Romania, Russian Federation, Germany, Netherlands, Turkey, Bulgaria, India, Taiwan, Czech Republic, Tunisia, Japan, Egypt, Israel, Korea, Republic of, Thailand
Dasman Diabetes Institute

Recruiting

Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients

Diabetes Mellitus, Type 2

Kuwait
University of Copenhagen
Gentofte Hospital, Denmark

Recruiting

The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function (H-21044858)

Incretin Effect

Denmark
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-F1)

Diabetes Mellitus, Type 2

United States, Brazil, Poland, Romania, Ukraine, Germany, Italy, Estonia, Malaysia, Philippines, Mexico, Lithuania, Colombia, Slovakia, Chile
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO)

Diabetes Mellitus, Type 2

United States, Poland, Romania, Russian Federation, Ukraine, India, Belgium, Mexico, Tunisia, Japan, Israel, Korea, Republic of
Sapporo Medical University
Merck Sharp & Dohme LLC

Completed

Is Glucagon-like Peptide-1 Insufficiency a Residual Risk in Coronary Artery Disease?

Coronary Artery Disease

Japan
Pfizer

Completed

Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects

Diabetes Mellitus, Type 2

United States
Radboud University Medical Center
Turku University Hospital; Charite University, Berlin, Germany; University Medical... and other collaborators

Unknown

GLP-1 Receptor Expression in CHI (GLP-1-CHI)

Congenital Hyperinsulinism

Netherlands
Eli Lilly and Company

Completed

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

Diabetes Mellitus, Type 2

India
Eli Lilly and Company

Completed

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Karl Neff
University College Dublin

Completed

The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease

Diabetic Kidney Disease

Ireland
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-M)

Diabetes Mellitus, Type 2

United States, Canada, Romania, Russian Federation, Ukraine, Germany, Spain, Philippines, Czech Republic, Mexico, Croatia, Chile, Morocco, South Africa, Australia, Venezuela
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-X)

Diabetes Mellitus, Type 2

United States, Brazil, Poland, Russian Federation, Germany, Italy, Netherlands, Spain, Sweden, Argentina, Denmark, Finland, Hungary, Norway, Colombia, Austria, Greece, Puerto Rico
University of Mississippi Medical Center

Recruiting

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score

Diabetes Mellitus, Type 2 | Osteoporosis, Postmenopausal

United States
Beijing Dongfang Biotech Co., Ltd.

Unknown

a Study of JY09 in Chinese Healthy Subjects

Healthy
Eli Lilly and Company

Active, not recruiting

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both (SURPASS-PEDS)

Glucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Type2 Diabetes | Metabolic Disease | T2DM (Type 2 Diabetes Mellitus) | T2D

United States, India, Australia, United Kingdom, Mexico, Brazil, Israel, France, Italy
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (SURPASS-2)

Type 2 Diabetes

United States, Puerto Rico, Australia, United Kingdom, Mexico, Argentina, Brazil, Israel, Canada
University of Pennsylvania

Completed

GLP 1 for Intraoperative Glycemic Control (GLP)

Hyperglycemia | Hypoglycemia

United States
University of Copenhagen

Completed

GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations

Obesity

Denmark
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS) (GETGOAL-MONO)

Diabetes Mellitus, Type 2

Japan
University Hospital, Gentofte, Copenhagen
University of Copenhagen

Completed

Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines (AlfaEx)

Glucose Metabolism Disorders

Denmark
Shanghai 10th People's Hospital

Unknown

Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status

Obesity

China
University of Padova
Azienda Ospedaliera di Padova

Unknown

GLP-1 REceptor Agonists and Real World EvIdeNce (GLP-1REWIN)

Type 2 Diabetes

Italy
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (GETGOAL-P)

Diabetes Mellitus Type 2

United States, Austria, Canada, France, Germany, Greece, Guatemala, India, Mexico, Peru, Puerto Rico, Romania, Turkey
Royal North Shore Hospital

Not yet recruiting

Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity (TZP-T1D)

Type 1 Diabetes Mellitus | Overweight and Obesity
Zoltan Pataky
University of Geneva, Switzerland

Completed

Reward Mechanisms in Obesity (LIRAOB)

Obesity

Switzerland
Eli Lilly and Company

Completed

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Peking Union Medical College Hospital

Unknown

Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients

Polycystic Ovary Syndrome

China
Radboud University Medical Center

Completed

GLP-1 Receptor Targeting in Diabetic and Healthy Individuals (GLP-1-CPOP)

Type 1 Diabetes

Netherlands
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin (GETGOAL-L)

Diabetes Mellitus, Type 2

United States, France, Canada, Brazil, Russian Federation, Germany, Italy, Turkey, India, Mexico, Egypt, United Kingdom, Korea, Republic of, Chile, Puerto Rico
University of Chicago

Completed

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

Monogenic Diabetes

United States
University Hospital, Gentofte, Copenhagen

Completed

GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake (GASOLIN)

Obesity | Type 2 Diabetes | Adiposity

Denmark
Eli Lilly and Company

Recruiting

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

Hepatic Insufficiency | Healthy

United States
Mayo Clinic
Merck Sharp & Dohme LLC

Completed

GLP1R Polymorphisms and Response to GLP1

Diabetes

United States
Assistance Publique - Hôpitaux de Paris

Completed

Effect of GLP-1 on Angiogenesis (ANGIOSAFE 1)

Type 2 Diabetes

France
University of Luebeck
Novo Nordisk A/S

Completed

Liraglutide Effects on Memory in Healthy Subjects

Healthy

Germany
Ganga Care Hospital, Nagpur

Completed

Association of Kisspeptin Levels With Insulin Secretion in Diabetes Mellitus

Diabetes Mellitus

India

Search clinical trials for: GLP-1 agonist

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations